Regulation of early endocytic vesicle motility and fission in a reconstituted system.
We previously established conditions to reconstitute kinesin-dependent early endocytic vesicle motility and fission on microtubules in vitro. The present study examined the question whether motility and fission are regulated in this system. Screening for proteins by immunofluorescence microscopy revealed that the small G protein, Rab4, was associated with 80% of hepatocyte-derived early endocytic vesicles that contain the ligand asialoorosomucoid (ASOR). By contrast, other markers for early endocytic vesicles including clathrin, Rab5 and EEA1 were present in the preparation but did not colocalize with the ASOR vesicles. Guanine nucleotides exchanged into the Rab4 present on the vesicles as shown by solubilization of Rab4 by Rab-GDI; solubilization was inhibited by incubation with GTP-gamma-S and promoted by GDP. Pre-incubation of vesicles with GDP increased the number of vesicles moving on microtubules and markedly increased vesicle fission. This increase in motility from GDP was shown to be towards the minus end of microtubules, possibly through activation of the minus-end-directed kinesin, KIFC2. Pre-incubation of vesicles with GTP-gamma-S, by contrast, repressed motility. Addition of exogenous GST-Rab4- GTP-gamma-S led to a further repression of motility and fission. Repression was not seen with addition of GST-Rab4-GDP. Treatment of vesicles with Rab4 antibody also repressed motility, and repression was not seen when vesicles were pre-incubated with GDP. Based on these results we hypothesize that endogenous Rab4-GTP suppresses motility of ASOR-containing vesicles in hepatocytes and that conversion of Rab4-GTP to Rab4-GDP serves as a molecular switch that activates minus-end kinesin-based motility, facilitating early endosome fission and consequent receptor-ligand segregation.
Bananis
Eustratios
E
Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Murray
John W
JW
Stockert
Richard J
RJ
Satir
Peter
P
Wolkoff
Allan W
AW
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001212:Asialoglycoproteins / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D002474:Cell-Free System; D002478:Cells, Cultured; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D011992:Endosomes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D006153:Guanosine Diphosphate / Q000378:metabolism / Q000494:pharmacology; D022781:Hepatocytes / Q000378:metabolism; D016547:Kinesins / Q000037:antagonists & inhibitors / Q000378:metabolism; D008024:Ligands; D008297:Male; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009961:Orosomucoid / Q000031:analogs & derivatives* / Q000378:metabolism; D021381:Protein Transport / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011956:Receptors, Cell Surface / Q000378:metabolism; D013347:Subcellular Fractions; D022161:Transport Vesicles / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D020695:rab4 GTP-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*
D000906:Antibodies; D001212:Asialoglycoproteins; C105219:KIFC2 protein, mouse; D008024:Ligands; D009419:Nerve Tissue Proteins; D009961:Orosomucoid; D011956:Receptors, Cell Surface; C017030:asialoorosomucoid; D006153:Guanosine Diphosphate; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D016547:Kinesins; D020695:rab4 GTP-Binding Proteins